ACLARION, INC. Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year
ACLARION, INC. (ACON) had Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year of $121.74 thousand as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Notes › Goodwill and Other › Intangible Asset, Finite-Lived, and Capitalized Cost, Software to be Sold, Leased, or Marketed, Estimated Amortization Expense
us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear · last filed 2026-08-06
- 2026-06-30: Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year $121.74K.
- 2026-03-31: Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year $180.17K.
- 2023-09-30: Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year $41.00K.
- 2023-06-30: Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year $81.10K.
| Period end | Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year |
|---|---|
| 2026-06-30 | $121.74K 10-Q · filed 2026-08-06 |
| 2026-03-31 | $180.17K 10-Q · filed 2026-05-13 |
| 2023-09-30 | $41.00K 10-Q · filed 2023-11-14 |
| 2023-06-30 | $81.10K 10-Q · filed 2023-08-25 |
| 2023-03-31 | $116.25K 10-Q · filed 2023-07-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Advanced Biomed Inc. (ADVB) | $0.009B | ||
| AMERICAN SHARED HOSPITAL SERVICES (AMS) | United States | $0.010B | -5.64 |
| BioNexus Gene Lab Corp (BGLC) | $0.004B | ||
| SERA PROGNOSTICS, INC. (SERA) | United States | $0.062B | -5.75 |
| Freenome, Inc. (FRNM) | United States | $0.143B | |
| EXAGEN INC. (XGN) | United States | $0.212B | -5.95 |
| BIODESIX INC (BDSX) | United States | $0.312B | |
| Fulgent Genetics, Inc. (FLGT) | United States | $0.593B | -6.70 |
| Lumexa Imaging Holdings, Inc. (LMRI) | United States | $0.951B | |
| CASTLE BIOSCIENCES INC (CSTL) | United States | $1.074B | -37.45 |